Natalizumab (Tysabri) Humanized, MAb Against α 4 subunit of α 4 β 1 Integrin. Multiple Sclerosis Treatment Update
|
|
- Joel Warner
- 6 years ago
- Views:
Transcription
1 Natalizumab (Tysabri) Humanized, MAb Against α 4 subunit of α 4 β 1 Integrin Complementarity-Determining Regions (CDRs) Multiple Sclerosis Treatment Update CDR grafted from murine Ab Human IgG 4 framework Retains full potency Human IgG 4 Framework Natalizumab Trial (AFFIRM) 2-Year Outcomes Placebo n315 Natalizumab n627 Natalizumab Trial (AFFIRM) Disability Progression 0.73 p % p % p % 1.9 Probability of Sustained Progression Week Sustained Hazard ratio0.58 P0.001 Placebo 29% Natalizumab 17% Week Probability of Sustained Progression Week Sustained Hazard ratio0.46 P0.001 Placebo 23% Natalizumab 11% Week Relapse Rate Gd+ Lesions New T2 Lesions Polman CH, et al. N Engl J Med. 2006;354:
2 Trial Phase II, RRMS AFFIRM, RRMS SENTINEL, RRMS Natalizumab Trials MS Clinical Activity MRI Activity Clinical Severity MRI Severity Significantly Improved (p0.01) Marginally Improved (p ) ns not improved Natalizumab Current Status 22,000 MS patients using Natalizumab world-wide 6,600 > 1 year RR-MS patients not adequately controlled on standard therapy, or tolerating standard therapy No new PML Hypersensitivity ( 2%) Hepatotoxicity 16 cases Two cases of malignant melanoma just reported The RERD Trial Study patients Relapsing Remitting MS Compared: IFNβ-1a 44 µg, s.c., tiw vs. 20 mg, s.c., qd years of age 1 attack within the prior 12 months Clinically stable in the prior 4 weeks EDSS score of n 764 Primary Time to first relapse Secondary The RERD Trial Main Study Endpoints Mean number of T2 active (new or enlarging) lesions per patient per scan Mean number of T1 gadolinium (Gd)-enhancing lesions per patient per scan Tertiary Combined unique active (CUA) lesions (new T1-Gd+/new or enlarging T2) Clinical Relapse rate Proportion relapse-free 3 month 1-point confirmed EDSS progression 2
3 The RERD Trial Time to First Relapse (1 o endpoint) The RERD Trial Other Outcomes days (96 weeks) Survival distribution function IFN beta-1a IFNβ-1a Hazard ratio (95% CI): (0.74, 1.21) p No significant difference in the hazard rates for time to EDSS progression (6 months sustained 1-point progression) The 3-month outcome was the pre-specified tertiary endpoint but patients were only seen once every 6 months No unexpected safety issues with either therapy th percentile: number of days to first attack Time to first relapse (days) Mikol DD, et al. ECTRIMS Abstract The RERD Trial Gd+ lesions (2 o endpoint) The Regard Trial Summary: Efficacy and Tolerability 0.5 *Mean number Gd+ lesions Mean* (SE) Treatment Difference -0.2 (0.1); p There was no clinical efficacy difference between Rebif 44 µg over in this patient population There was an advantage of Rebif 44 µg over Copaxone on some MRI activity measures The safety and tolerability of both Rebif 44 µg and 20 mg was again demonstrated IFN beta-1a (n 230) (n 230) *Mean number per patient per scan CI confidence interval; glatiramer acetate; SE standard error. 3
4 The BEYOND Trial Study Design Phase III, randomized, multi-center study Double-blind Betaseron 250 µg Rater-blinded Betaseron 500 µg Rater-blinded Copaxone 20 mg 2,244 patients randomized from 198 sites in 26 countries, 2,220 at SoT Yearly MRIs: central, blinded evaluation Treatment duration: at least 2 years Treatment-naïve RRMS patients (Diagnosis McDonald 2001) Enrollment completed end of June 2005 Last patient last visit on August 8, 2007 Primary The BEYOND Trial Main Study Endpoints Relapse Risk (Hazard ratio for time to recurrent relapses) Supportive Relapse-Related Outcomes Secondary Relapse Rate, Time to 1 st relapse, Proportion relapse-free Time to confirmed EDSS progression MRI Black holes Other Endpoints Yearly MRI measures: Burden of disease, atrophy, new T2 lesions NAbs MSFC QoL The BEYOND Trial Relapse Risk (1 o Endpoint) The BEYOND Trial Other Outcomes No significant difference in Relapse Risk between any group Betaseron 500 vs. Betaseron 250 Betaseron 250 vs. Copaxone Betaseron 500 vs. Copaxone P-values (one-sided) P0.16 P0.73 P0.43 Primary Analysis Sensitivity Analysis (no major protocol violations, 100% of doses, post-hoc) P-values (one-sided) P0.29 P0.30 P0.18 Supportive relapse-based outcomes and most of the other MRI outcome measures also show no differences between the three treatment groups. No difference in EDSS progression between groups hazard ratio estimate (± 95% CI) hazard ratio estimate (± 95% CI) 4
5 The BEYOND Trial Volume of T2 Lesions The BEYOND Trial Number of New T2 Lesions - 32% ; p % ; p % ; p % ; p Change in T2 Lesion Volume % 17.3% Mean New T2 Lesions µg 250 µg 20mg µg 250 µg 20mg The BEYOND Trial Efficacy, Tolerability and Adherence The BEYOND and RERD Trials Summary There was no clinical efficacy advantage of 500 µg over 250 µg or of either dose over in this patient population There was an advantage of 250 and 500 µg over on some MRI measures of activity and severity The safety and tolerability of 250 µg and was again demonstrated. Effects Attack Rate EDSS Progression MRI Activity MRI Severity Side Effects Flu Like Sx Injection Site Reactions LFT Abnormalities Depression IFNβ-1a 44µg 250µg 20mg 5
6 AFFIRM, BEYOND, and RERD Trials Relapse Rates (Before and After Rx) Several Clinical Trials Baseline Demographics 2 Year Prior to Rx After Rx Year of Study Start BEYOND (n2244) 2003 AFFIRM (n942) 2001 RERD (n764) 2004 Pivotal (n372) Age (mean) Annual Attack Rate % -79% -70% Mean Disease Duration (years) Mean relapses in prior year EDSS 2.0 (% patients) EDSS (mean) % % na 33% na 18% AFFIRM BEYOND RERD Gd-enhancement (%) Number of Gd+ lesions (mean) 47% % % 1.6 na na Event Rates in MS Clinical Trials Summary of the On-Drug Experience Future MS Therapies Currently Being Tested COP 1 MSCRG PRISMS OWIMS EVIDENCE AFFIRM By Date of Study End CAMPATH R CAMPATH RERD R RERD BEYOND HD BEYOND LD BEYOND Oral Therapies FTY-720, Fingolimod Teriflunomide Fumarate, BG-12 Laquinimod Cladribine Riluzole VLA4-inhibitors (many) Infusions Alemtuzumab (Campath) Anti-CD20 rituximab, ocrelizumab Daclizumab (Zenapax) Anti-IL12 MBP8298 TCR vaccine
7 Rituximab Trial Anti-CD20 MAb Rituximab Trial in RRMS Phase II Study Design Screen (4 wks) Treatment period (48 wks) Rituximab is a genetically engineered chimeric (mouse-human) monoclonal antibody that targets CD20-positive B lymphocytes CD20 is expressed on B and pre-b lymphocytes but not on stem cells or plasma cells MRI Week Long duration of action FDA approval for B-cell lymphoma (1997) and RA (2006) Rituximab/ Placebo Infusion Wk 4 MRI to evaluate safety Primary Endpoint Total number of Gd-enhancing lesions at Wks 12, 16, 20, and 24 Secondary Endpoints Proportion of patients relapsing Wks 0-24 New Gd-enhancing lesions T2 lesion volume changes B/L-Wk 24 Rituximab Trial Gd+ Lesions Rituximab Trial in RRMS % Relapsing 24 Weeks Placebo (n35) Rituximab (n69) p-value (n104) Proportion with Relapses 12 (34.3%) 10 (14.5%) Weeks Placebo (n35) Rituximab (n69) p-value (n104) Proportion with Relapses 14 (40.0)% 14 (20.3%) Mean New Gd+ Lesions by Week 7
8 Rituximab Trial in RRMS T2 Lesion Volume Rituximab in NMO Trial Inclusion Criteria T2 Lesion Volume Change from Baseline to Week 24**, mm 3 Mean ± SD 436 ± ± 1188 T2 Lesion Volume Change from Baseline to Week 36**, mm 3 Mean ± SD Placebo (n35) 417 ± 1305 Rituximab (n68) -175 ± 1188 p-value Criteria for Neuromyelitis Optica: a) ATM and ON occurring within 30 days of each other followed by a second attack > 3 months later b) ATM followed by ON > 3 months later c) ON followed by ATM > 3 months later 2. Criteria for patients at high risk for Neuromyelitis Optica: a) recurrent idiopathic ATM with >3 months between attacks b) recurrent bilateral simultaneous ON with >3 months between attacks. 3. Subjects should also have no clinical evidence of disease outside the optic nerve or spinal cord. Study Status: Still Enrolling Riluzole Trial Phase II Study Riluzole Trial Phase II Study Riluzole modulates kainate and NMDA receptors: Inactivation of voltage-dependant Na + channels on glutamatergic terminals Inhibition of pre-synaptic release of glutamate Noncompetitive blockade of post-synaptic NMDA channels Activation of G protein-dependant pathway Induces astrocyte-derived neurotrophic factors that promote survival of motor neurons MRI: Study Drug: Months: - 4 Screen Primary Secondary Riluzole / placebo treatment period (104 weeks) IFNβ-1a (Avonex) treatment period (92 weeks) Endpoint Efficacy Outcome Measures Progression of atrophy (SIENA) (n40) Progression of gray matter and white matter atrophy (SIENAX) Changes on EDSS, MSFC, MFIS, cognitive testing, MSQLI Changes in T1 and T2 lesion volume Change in glutamate and NAA 8
9 Riluzole Trial Inclusion Criteria RR or CIS within one year of onset years At least 2 silent T2 on brain and spinal cord MRI No IFNB exposure Copaxone discontinued for 3 months No corticosteroids/exacerbation previous 8 weeks Patient willing to begin Avonex at month 3 Normal LFT ( 2 x ULN) Study Status: Still Enrolling Sphingosine 1-phosphate (S1P) receptor modulator FTY720 LN FTY-720 (Fingolimod) Mode of Action FTY720: traps circulating lymphocytes in peripheral LN prevents T-cell invasion of CNS T cell S1P receptor FTY720-P internalizes S1P 1, blocks lymphocyte egress from LN while sparing immune surveillance by peripheral memory T cells FTY-720 (Fingolomod) Trial Entry Criteria MBP8298 Trial in SPMS Inclusion Criteria Patients with RRMS (2005 revised McDonald criteria) 18 through 55 years of age 1 documented relapse during the previous year or 2 documented relapses during prior 2 years EDSS score of No relapse or steroid treatment within prior 30 days. Age: years of age SPMS, with progression and HLA DR 2 and/or 4 positive Absence of relapse in the prior 3 months EDSS: Pyramidal or Cerebellar FSS 2 Study Still Enrolling Study Status: Still Enrolling 9
10 New Therapy Update Conclusions There are many new and, more importantly, potentially really exciting therapies coming into the MS therapeutic armamentarium. However, we must be wary of forming hasty conclusions from crosstrial comparisons of new therapies vs. old. The populations of study may be very different. We must also remember to be cautious with regard to our opinion about the safety of new agents. Long-term safety is never guaranteed by short-term trials. Perhaps, our experience with the safety of IFNβ and over time was just blind-luck. 10
CIBMTR Center Number: CIBMTR Recipient ID: RETIRED. EBMT Center Identification Code (CIC): Today s Date:
Multiple Sclerosis Pre-HSCT Data EBMT Center Identification Code (CIC): Today s Date: Sequence Number: Date Received: Registry Use Only Date of HSCT for which this form is being completed: & 20 20 HSCT
More informationForm 2043 R3.0: Multiple Sclerosis Pre-HSCT data
Key Fields Sequence Number: Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: EBMT Center Identification Code (CIC): Today's Date: - - Date of HSCT for which this form is being completed: -
More informationUpdate on New MS Therapeutics
Update on New MS Therapeutics William Meador, MD Assistant Professor AAN August 2017 Meeting Disclosures Clinical Trial Involvement: SPRINT-MS Trial MediciNova, ibudilast LemCog Sanofi/Genzyme, alemtuzumab
More informationThere are currently 4 US Food and Drug
DISEASE-MODIFYING THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS* Benjamin M. Greenberg, MD, MHS ABSTRACT Four major disease-modifying therapies are discussed within the context of relapsing and remitting
More informationAubagio (teriflunomide tablets) Policy Number: Last Review: 07/2017 Origination: 07/2014 Next Review: 07/2018
Aubagio (teriflunomide tablets) Policy Number: 5.01.614 Last Review: 07/2017 Origination: 07/2014 Next Review: 07/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for
More informationMultiple Sclerosis Agents Drug Class Prior Authorization Protocol
Multiple Sclerosis Agents Drug Class Prior Authorization Protocol Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 This policy has been developed through review
More informationPipeline Drug Evidence Review: Ocrevus (ocrelizumab) vs. Tysabri, Lemtrada, Rebif and Tecfidera June 8, 2016
For more information contact us Pipeline Drug Evidence Review: Ocrevus (ocrelizumab) vs. Tysabri, Lemtrada, Rebif and Tecfidera June 8, 2016 Copyright. 2016 Advera Health Analytics, Inc. All rights reserved.
More informationClinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis
Journal of Central Nervous System Disease Review Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Clinical Utility of Glatiramer Acetate in the Management
More informationNational MS Society Information Sourcebook
National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook Interferons The interferons are a group of natural proteins that are produced by human cells in response to viral infection
More informationLEMTRADA (ALEMTUZUMAB)
LEMTRADA (ALEMTUZUMAB) UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: 2017D0023O Effective Date: June 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationLEMTRADA (ALEMTUZUMAB)
LEMTRADA (ALEMTUZUMAB) UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: 2018D0023P Effective Date: April 1, 2018 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationOutline. References. Marshall,1
Outline Multiple Sclerosis: More Than Your ABC s Janene L. Marshall, PharmD, BCPS Clinical Associate Professor Internal Medicine Clinical Pharmacist Chicago State University College of Pharmacy J-marshall@csu.edu
More informationEmerging Therapies for the Management of Multiple Sclerosis
Clinical Medicine Insights: Therapeutics R e v i e w Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Emerging Therapies for the Management of Multiple Sclerosis
More informationAdvances in Immunomodulatory Therapy for Multiple Sclerosis
Advances in Immunomodulatory Therapy for Multiple Sclerosis Sona Narula, MD Children s Hospital of Philadelphia, Philadelphia, Pennsylvania Abstract Significant research has been directed toward the development
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Multiple Sclerosis Agents Page 1 of 18 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Multiple Sclerosis Agents Tysabri (natalizumab) and Lemtrada (alemtuzumab),
More informationTysedmus, a Registry of Multiple Sclerosis patients exposed to Natalizumab
PHARMACOVIGILANCE AND REGISTRY PROGRAMMES Tysedmus, a Registry of Multiple Sclerosis patients exposed to Natalizumab Eric Van Ganse Pharmacoepidemiology, CHU-Lyon France OUTLINE I. GOOD REGISTRY PRACTICE
More informationThe Cost-Effectiveness of Treatment Options for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: Modeling Analysis Plan
The Cost-Effectiveness of Treatment Options for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: Modeling Analysis Plan October 7, 2016 Prepared for Institute for Clinical and Economic Review,
More informationTiming is Everything: The Importance of Early Intervention in Multiple Sclerosis
Timing is Everything: The Importance of Early Intervention in Multiple Sclerosis Challenge Question: Pathophysiology Which of the following is a correct statement about the pathophysiology of MS and/or
More informationA Multiple Treatment Comparison of Eleven Disease- Modifying Drugs Used for Multiple Sclerosis
Original Article J Clin Med Res. 2018;10(2):88-105 A Multiple Treatment Comparison of Eleven Disease- Modifying Drugs Used for Multiple Sclerosis Vida Hamidi a, Elisabeth Couto a, Tove Ringerike a, Marianne
More informationDimethyl Fumarate and Peginterferon β-1a: New Insights Into the Pivotal Trials
Dimethyl Fumarate and Peginterferon β-1a: New Insights Into the Pivotal Trials Pavan Bhargava, MD Johns Hopkins University School of Medicine, Baltimore, Maryland Abstract Treatment options for multiple
More informationThe Latest Innovations in the Drug Pipeline for Multiple Sclerosis
CLINICAL SPECIAL FEATURE The Latest Innovations in the Drug Pipeline for Multiple Sclerosis Lea Radick and Stanton R. Mehr Am Health Drug Benefits. 2015;8(8):448-453 www.ahdbonline.com Disclosures are
More informationCommon Drug Review Pharmacoeconomic Review Report
Common Drug Review Pharmacoeconomic Review Report October 2014 Drug Teriflunomide (Aubagio) (14 mg film-coated tablet) Indication Teriflunomide is indicated as monotherapy for the treatment of patients
More informationClinical Policy: Multiple Sclerosis Reference Number: CP.CPA.206 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: Reference Number: CP.CPA.206 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationGuideline on similar biological medicinal products containing interferon beta
1 2 3 15 December 2011 EMA/CHMP/BMWP/652000/2010 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 Guideline on similar biological medicinal products containing interferon beta 7 Draft Draft
More informationREVIEW ARTICLE. Immunomodulatory Agents for the Treatment of Relapsing Multiple Sclerosis. (MS) is a multifocal, demyelinating disease
Immunomodulatory Agents for the Treatment of Relapsing Multiple Sclerosis A Systematic Review REVIEW ARTICLE Steven L. Galetta, MD; Clyde Markowitz, MD; Andrew G. Lee, MD Background: Within the past 10
More informationCurrent and Emerging Therapies in Multiple Sclerosis: A Systematic Review
University of Connecticut DigitalCommons@UConn Articles - Research University of Connecticut Health Center Research 7-2012 Current and Emerging Therapies in Multiple Sclerosis: A Systematic Review Wanda
More informationPrior Authorization Form
5/2/2017 Prior Authorization Form INTOTAL HEALTH PLAN (SPC) Multiple Sclerosis MMT SGM This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign
More informationDirucotide (MBP8298) for the treatment of multiple sclerosis
DRUG EVALUATION Dirucotide (MBP8298) for the treatment of multiple sclerosis Clyde Markowitz University of Pennsylvania, 3 West Gates Building, 3400 Spruce Street, Philadelphia, PA 19104, USA Tel.: +1
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Multiple Sclerosis Agents Page 1 of 17 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Multiple Sclerosis Agents Tysabri (natalizumab) and Lemtrada (alemtuzumab)
More informationTITLE OF PRESENTATION SECOND QUARTER 2014 FINANCIAL RESULTS & BUSINESS UPDATE
TITLE OF PRESENTATION SECOND QUARTER 2014 FINANCIAL RESULTS & BUSINESS UPDATE JULY 23, 2014 Forward-Looking Statements This presentation contains forward-looking statements, including statements about
More informationCredit Suisse 7 th Annual European Large Cap Pharmaceutical Conference. November 6, 2007
Credit Suisse 7 th Annual European Large Cap Pharmaceutical Conference November 6, 2007 Safe Harbor Statement This presentation contains forward-looking statements about Elan s financial condition, results
More informationAs the disease progresses, patients may experience suboptimal response to their current therapy, necessitating a treatment switch.
Comments to ICER s Disease-Modifying Therapies for Relapsing-Remitting and Primary-Progressive Multiple Sclerosis: Effectiveness and Value Draft Evidence Report We acknowledge the difficult nature of comparing
More informationA Phase I/IIa Study of Human Anti-CD38 Antibody MOR03087 in Relapsed/Refractory Multiple Myeloma
1 von 5 10.12.2013 10:33 A service of the U.S. National Institutes of Health Trial record 1 of 1 for: MOR202C101 Previous Study Return to List Next Study A Phase I/IIa Study of Human Anti-CD38 Antibody
More informationReview of week-24 results
Review of week-24 results GNC-003: an international, double-blind, randomized, placebo-controlled phase IIb trial to assess the efficacy, safety and pharmacokinetics of in patients with relapsing remitting
More informationPATIENT GROUPS & CLINICAL TRIALS CASE STUDY
February 1, 2017 PATIENT GROUPS & CLINICAL TRIALS CASE STUDY Jeffrey W. Sherman, M.D., FACP Past President Inaugural Fellow Chief Medical Officer Executive Vice President Disclaimer The views and opinions
More informationReview of Phase IIb week-24 results
The leader in the treatment of HERV-mediated diseases Review of Phase IIb week-24 results As presented at MS Paris 2017 October 30, 2017 www.geneuro.com Disclaimer This presentation has been prepared by
More informationThe Science of Monoclonal Antibody Therapy: Introducing Canine Atopic Dermatitis Immunotherapeutic*
The Science of Monoclonal Antibody Therapy: Introducing Canine Atopic Dermatitis Immunotherapeutic* *This product license is conditional. Efficacy and potency test studies are in progress. Michele Rosenbaum,
More informationREFCTRI/2010/ CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Sun, 18 Feb 2018 17:17:30 GMT) CTRI Number CTRI/2010/091/000254 [Registered on: 09/09/2010] - Last Modified On 05/03/2013 Post Graduate Thesis Type of Trial
More informationAntisense Therapeutics Ltd ASX:ANP January 2017
Antisense Therapeutics Ltd ASX:ANP January 2017 Forward Looking Statements This presentation contains forward-looking statements regarding the Company s business and the therapeutic and commercial potential
More informationACTELION TRANSFORMATION ON THE WAY. Jean-Paul Clozel Chief Executive Officer. Copyright 2016 Actelion Pharmaceuticals Ltd
ACTELION 2015 2020 TRANSFORMATION ON THE WAY Jean-Paul Clozel Chief Executive Officer Copyright The following information contains certain forward-looking statements, relating to the company s business,
More informationEmerging Medical Therapies in Inflammatory Bowel Disease
Emerging Medical Therapies in Inflammatory Bowel Disease - 2017 Nir Modiano, MD, PhD Assistant Professor of Medicine Division of Gastroenterology & Hepatology Director, Inflammatory Bowel Disease Program
More informationA look into the future - International Progressive MS Alliance. Dr Dhia Chandraratna Head of Research, MSIF
A look into the future - International Progressive MS Alliance Dr Dhia Chandraratna Head of Research, MSIF Neurologist: Accumulation of disability Gradual change over time Imager: Defining Progressive
More informationwww.ms-coalition.org February 14, 2014 Janet Woodcock, MD Director, Center for Drug Evaluation and Research Food and Drug Administration 10903 New Hampshire Ave Silver Spring, MD 20993 Re: Implications
More informationComparison of three cytokine release assays (CRA) for hazard. syndrome potential of monoclonal
Comparison of three cytokine release assays (CRA) for hazard identification of cytokine release syndrome potential of monoclonal antibody (mab) therapeutics ti Madeline Fort HESI ITC Cytokine Release Assay
More informationBiologics in IBD: Optimizing Therapies and Emerging Agents
Optimizing Therapies and Emerging Agents Peter Mannon, MD Professor of Medicine and Microbiology UAB AGS Annual Conference July 1, 2017 Hilton Sandestin Optimizing Therapies and Emerging Agents Optimizing
More informationPassive vaccination as a global strategy for preventing RSV disease in infants. Filip Dubovsky MD MPH FAAP MedImmune March 2016
Passive vaccination as a global strategy for preventing RSV disease in infants Filip Dubovsky MD MPH FAAP MedImmune March 2016 Outline for Presentation Rationale for passive immunization for RSV prophylaxis
More informationDeveloping Therapeutics for the Treatment of Multiple Sclerosis
NeuroRx : The Journal of the American Society for Experimental NeuroTherapeutics Developing Therapeutics for the Treatment of Multiple Sclerosis David J. Virley Neurology and GI Centre of Excellence for
More informationTo Our Shareholders: Reaching Patients with PNH and ahus
To Our Shareholders: In 2014, Alexion continued to expand its commercial and clinical operations as we advanced our mission to develop and deliver life-transforming therapies for patients with severe and
More informationOcrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
The new england journal of medicine Original Article versus Interferon Beta-1a in Relapsing Multiple Sclerosis S.L. Hauser, A. Bar Or, G. Comi, G. Giovannoni, H.-P. Hartung, B. Hemmer, F. Lublin, X. Montalban,
More informationComparability Studies for Autologous Cell Therapy Products. Chris Shen July, 2017
Comparability Studies for Autologous Cell Therapy Products Chris Shen July, 2017 Forward Looking Statements/Safe Harbor To the extent statements contained in this presentation are not descriptions of historical
More informationPhase 1 SMA Type 2 Trial Initiation and Study Design. December 2017
Phase 1 SMA Type 2 Trial Initiation and Study Design December 2017 Disclaimers This presentation contains forward-looking statements, including statements about: the timing, progress and results of preclinical
More informationUse of Antisense Oligonucleotides for the Treatment of Inheritable Rare Disorders. C. Frank Bennett Isis Pharmaceuticals
Use of Antisense ligonucleotides for the Treatment of Inheritable Rare Disorders C. Frank Bennett Isis Pharmaceuticals Agenda Review different antisense strategies Delivery of oligonucleotides to the skin,
More informationQuantification of Neutralizing Antibodies to Biopharmaceuticals using a Novel Cell- Bassed Assay Platform Technology
Quantification of Neutralizing Antibodies to Biopharmaceuticals using a Novel Cell- Bassed Assay Platform Technology Michael G Tovey, Director, Laboratory of Viral Oncology, Institut André Lwoff, Villejuif,
More informationThe rheumatoid arthritis drug development model: a case study in Bayesian clinical trial simulation
The rheumatoid arthritis drug development model: a case study in Bayesian clinical trial simulation Richard Nixon, Modeling and Simulation, Novartis PSI journal club, 2010 March 24 1 Bayesian clinical
More informationjournal of medicine The new england A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis Abstract
The new england journal of medicine established in 1812 march 2, 2006 vol. 354 no. 9 A Randomized, -Controlled Trial of for Relapsing Multiple Sclerosis Chris H. Polman, M.D., Paul W. O Connor, M.D., Eva
More informationDenosumab for the prevention of skeletal related events in patients with multiple myeloma first line
NIHR Innovation Observatory Evidence Briefing: April 2017 Denosumab for the prevention of skeletal related events in patients with multiple myeloma first line NIHRIO (HSRIC) ID: 6619 NICE ID: 8815 LAY
More informationRESEARCH PAPER. Multiple sclerosis
Additional material is published online only. To view please visit the journal online (http:// dx. doi. org/ 10. 1136/ jnnp- 2016-314843). For numbered affiliations see end of article. Correspondence to
More informationImmunogenicity of biotherapeutics; an introduction
Immunogenicity of biotherapeutics; an introduction PKUK 6 th November 2014 Hishani Kirby PhD, UCB Contents Background The importance of understanding Anti drug antibodies (ADAs) The immune response Factors
More informationClinical Trials in Multiple Sclerosis 2007: Planned, In Progress, Recently Completed
Clinical Trials in Multiple Sclerosis 2007: Planned, In Progress, Recently Completed This listing is prepared on behalf of the National Multiple Sclerosis Society s Advisory Committee on Trials of New
More informationFor personal use only
Antisense Therapeutics Ltd AGM Presentation and Questions on notice November, 2016 Forward Looking Statements This presentation contains forward-looking statements regarding the Company s business and
More informationDeveloping innovative new medicines for acute and chronic neurological and psychiatric conditions Larry Glass, CEO
Developing innovative new medicines for acute and chronic neurological and psychiatric conditions Larry Glass, CEO (lglass@neurenpharma.com) Neuren Pharmaceuticals Created to commercialize University of
More informationThe promise of T cell engineering CD19 CAR therapy A prologue to immune regenerative medicine Vast potential, patience, public education
The promise of T cell engineering CD19 CAR therapy A prologue to immune regenerative medicine Vast potential, patience, public education Academies Cell Therapy Workshop Washington, October 13, 2016 Michel
More informationGetReal: Clinical effectiveness in drug development
GetReal: Clinical effectiveness in drug development Mike Chambers Matthias Egger WP4 Leaders GSK, UK Univ. of Berne, Switzerland BBS/EFSPI Seminar Basel 04Jun13 Egger/Chambers: real world evidence in HTA
More informationJanuary (San Francisco, CA) January 8, 2018
January 2017 J.P. Morgan 36 th Annual Management Healthcare Presentation Conference (San Francisco, CA) January 8, 2018 DISCLAIMER Certain information contained in this presentation relates to or is based
More informationFDA Perspective on the Preclinical Development of Cancer Vaccines
FDA Perspective on the Preclinical Development of Cancer Vaccines Richard D. McFarland Ph.D., M.D. Medical Officer CBER/OCTGT/DCEPT mcfarlandr@cber.fda.gov Cancer Vaccine Clinical Trials Workshop Alexandria,
More informationSecond Quarter 2017 Financial Results. August 8, 2017
Second Quarter 2017 Financial Results August 8, 2017 Agios Conference Call Participants Prepared Remarks Introduction RENEE LECK, Sr. Manager, Investor Relations Business Highlights & 2017 Key Milestones
More informationOVERVIEW OFSEP: COHORT INNOVATION DAY 105
: Observatoire Français de la Sclérose en Plaques ITMO Santé publique Lyon Sandra Vukusic, M.D., Ph.D. Professor of Neurology Lyon University Hospital OVERVIEW AT A GLANCE > Neurology > Multiple Sclerosis
More informationA BS TR AC T. n engl j med 367;12 nejm.org september 20,
The new england journal of medicine established in 1812 september 20, 2012 vol. 367 no. 12 -Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis Robert J. Fox, M.D., David H. Miller,
More informationJournal of Interferon & Cytokine Research The Official Publication of the International Society for Interferon and Cytokine Research
Journal of Interferon & Cytokine Research The Official Publication of the International Society for Interferon and Cytokine Research Editors-in-Chief Ganes C. Sen Department of Molecular Genetics NE20
More informationMomenta Pharmaceuticals, Inc. 36 th Annual J.P. Morgan Healthcare Conference
Momenta Pharmaceuticals, Inc. 36 th Annual J.P. Morgan Healthcare Conference January 8, 2018 Forward-Looking Statements This presentation contains forward-looking statements about our financial outlook,
More informationTechnology Overview. 1. Background of Technology. (1) Regulatory Status
Apimeds, Inc. 1 Technology Overview 1. Background of Technology (1) Regulatory Status - New Drug Approval of KFDA (The 6th New Drugs in Korea, The first natural biological drug of its kind). The animal
More informationISPOR 18th Annual European Congress Tuesday 10 November,13:45-14:45
ISPOR 18th Annual European Congress Tuesday 10 November,13:45-14:45 Introduction Alastair Kent, OBE, Genetic Alliance UK, London, UK Recent HTA decisions Jacco Keja, PhD, IMS Health, Rotterdam, The Netherlands
More informationSamatasvir (IDX719), a Potent Pan-Genotypic NS5A Inhibitor, for the Treatment of Hepatitis C Virus (HCV) Infection
Samatasvir (IDX719), a Potent Pan-Genotypic NS5A Inhibitor, for the Treatment of Hepatitis C Virus (HCV) Infection Douglas Mayers, MD December 11, 2013 1 Idenix: Advancing All-Oral, Pan-Genotypic Combination
More informationHEALTH TECHNOLOGY ASSESSMENT
HEALTH TECHNOLOGY ASSESSMENT VOLUME 21 ISSUE 52 SEPTEMBER 2017 ISSN 1366-5278 Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic
More informationThe New News in Stem Cell Research Andrés Bratt-Leal, PhD 12/1/2017
The New News in Stem Cell Research Andrés Bratt-Leal, PhD 12/1/2017 Cell Therapy and Parkinson s Disease Very specific neural degeneration >50% of DA neurons are gone by diagnosis 1 million in the USA,
More informationUnderstanding clinical research trials
Understanding clinical research trials Dr. Isabelle Fleury Medical Hemato-oncologist Hôpital Maisonneuve-Rosemont CIUSSS de l Est-de-l Île-de-Montréal Goals of this presentation Better understand clinical
More informationOPT-302: a VEGF-C/VEGF-D Trap for wet AMD
OPT-302: a VEGF-C/VEGF-D Trap for wet AMD Ophthalmology Innovation Summit, Nov 12 2015 Circadian Technologies (ASX:CIR, OTCQX:CKDXY) Megan Baldwin PhD, CEO & MD megan.baldwin@opthea.com 2 Disclaimer Investment
More informationAnti- THrombosis with Enoxaparin in intubated Adolescents
Anti- THrombosis with Enoxaparin in intubated Adolescents E. Vincent S. Faustino, MD, MHS October 2017 NHLBI submission S L I D E 0 Research question, central hypothesis and primary aim Research Question
More informationKlaus Romero MD MS FCP. (Supported by the CAMD AD Modeling & Simulation Team)
Baseline ICV-adjusted Hippocampal Volume as a Biomarker for Enrichment in Alzheimer s Disease Trials Co-Chairs: Patricia Cole (Takeda) & Derek Hill (IXICO) A Modeling Approach to Demonstrate Trial Enrichment
More informationDefining Clinical Benefit in Clinical Trials: FDA Perspective
Defining Clinical Benefit in Clinical Trials: FDA Perspective Jessica J. Lee, MD, MMSc Medical Team Leader Division of Gastroenterology and Inborn Errors Products Center for Drug Evaluation and Research
More informationCopyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.
Statutory Framework for Biologics Drugs Investigational Use Application IND Pre-Market Approval Applications 505(b)(1) NDA 505(b)(2) NDA 505(j) ANDA Over-the-Counter (OTC) Non- Rx Drugs Monograph Biologics
More informationNew Hope For Serious Infections
New Hope For Serious Infections Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning
More informationCurrent Trends in Specialty Pharmacy Management. priorityhealth.com
Current Trends in Specialty Pharmacy Management A little background Priority Health members fill about 25,000 prescriptions every day We spend over $1,250,000 a day on prescriptions Over 80% of all prescriptions
More informationDifferential glatiramer acetate treatment persistence in treatment-naive patients compared to patients previously treated with interferon
Fernández-Fournier et al. BMC Neurology (2015) 15:141 DOI 10.1186/s12883-015-0399-9 RESEARCH ARTICLE Differential glatiramer acetate treatment persistence in treatment-naive patients compared to patients
More informationMapi Pharma Value-Added High-Barrier to Entry Pharmaceuticals Q4 2014
Mapi Pharma Value-Added High-Barrier to Entry Pharmaceuticals Q4 2014 1 Corporate Overview Strategy Growth Engines Building a vertically integrated, diversified, risk mitigated business model with high-barrier,
More informationDaniel Harari 1, *, Irit Orr 2, Ron Rotkopf 2, Sergio E. Baranzini 3 and Gideon Schreiber 1, * Abstract. Introduction ORIGINAL ARTICLE
Human Molecular Genetics, 2015, Vol. 24, No. 11 3192 3205 doi: 10.1093/hmg/ddv071 Advance Access Publication Date: 26 February 2015 Original Article ORIGINAL ARTICLE A robust type I interferon gene signature
More informationDocument number (version): RMP.NUS (3.0) Page 63 of 95
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology The immune system is the body s frontline defence to fight infection by viruses, bacteria, and other foreign organisms/materials.
More informationDEVELOPING FIRST-IN-CLASS TREATMENTS IN HAEMATOLOGIC CANCERS
DEVELOPING FIRST-IN-CLASS TREATMENTS IN HAEMATOLOGIC CANCERS DEUTSCHE BANK 42ND ANNUAL HEALTH CARE CONFERENCE MAY 4, 2017 LUIGI COSTA, CEO Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo, Norway www.nordicnanovector.com
More informationThe science behind Betalutin : why is it unique? Roy H. Larsen PhD Sciencons AS, Oslo, Norway
The science behind Betalutin : why is it unique? Roy H. Larsen PhD Sciencons AS, Oslo, Norway Speaker credentials Roy H. Larsen, PhD >25 years of experience in research on targeted radionuclide therapy
More information8. Clinical Trial Assessment Phase II
8. Clinical Trial Assessment Phase II Junko Sato, PhD Office of New Drug I, PMDA Disclaimer: The information within this presentation is based on the presenter s expertise and experience, and represents
More informationWhat s the difference? Challenges in pre-clinical development of biologics
Biologics vs Small MW NCEs What s the difference? Challenges in pre-clinical development of biologics Peter Lloyd Joint Conference of EU Human Pharmacological Societies and 20 th Anniversary of AGAH 31
More informationNew Hope For Serious Infections. Jefferies 2016 Healthcare Conference June 7-10, 2016 Grand Hyatt, New York City
New Hope For Serious Infections Jefferies 2016 Healthcare Conference June 7-10, 2016 Grand Hyatt, New York City Forward-Looking Statements These slides and the accompanying oral presentation (the Presentation
More informationCorporate Presentation. April 2016
Corporate Presentation April 2016 1 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationBETRIXABAN TO PREVENT PE, DVT, STROKE: MEDICALLY ILL PATIENTS Samuel Z. Goldhaber, MD Director, Thrombosis Research Group Section Head, Vascular
BETRIXABAN TO PREVENT PE, DVT, STROKE: MEDICALLY ILL PATIENTS Samuel Z. Goldhaber, MD Director, Thrombosis Research Group Section Head, Vascular Medicine Cardiovascular Division Brigham and Women s Hospital
More informationThe quality of reports of randomized trials in multiple sclerosis: a review
444327MSJ18610.1177/1352458512444327Signori et al.multiple Sclerosis Journal 2012 Topical Review MULTIPLE SCLEROSIS JOURNAL MSJ The quality of reports of randomized trials in multiple sclerosis: a review
More informationRACING TOWARD A CURE FOR BLOOD CANCERS WITH NEW CARS (CAR-T CELL THERAPY)
RACING TOWARD A CURE FOR BLOOD CANCERS WITH NEW CARS (CAR-T CELL THERAPY) Larry D. Anderson, Jr, MD, PhD Internal Medicine Grand Rounds University of Texas Southwestern Medical Center March 9, 2018 This
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm High-Dose Chemotherapy and Stem Cell Transplantation in the Era of Novel Therapies Larry Anderson, MD, PhD Multiple Myeloma and Stem Cell Transplant
More informationAppraisal of Beta Interferon/ Glatiramer for Multiple Sclerosis Final Appraisal Determination
Appraisal of Beta Interferon/ Glatiramer for Multiple Sclerosis Final Appraisal Determination Please note this document has been issued to consultees for the appeal period. It does not constitute guidance
More information